Q-omics provides the consensus-scored KANSL1 profile across patient tissues and cancer cell-line models. KANSL1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, KANSL1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, KANSL1 protein abundance shows 22,629 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KIRP, and GBM as cancer lineages where KANSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANSL1 survival associations across molecular data types. KANSL1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANSL1 RNA expression–survival associations across cancer types. High KANSL1 expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in SCLC, BRCA and THYM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for KANSL1 RNA expression.
This table summarizes KANSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KANSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANSL1 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRP, LIHC, HNSC and CHOL. The KIRP box plot shows higher KANSL1 RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with KANSL1 in patient tissues and cancer cell lines. In patient samples, KANSL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KANSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
